Drug Trial Radar · NCT07435129
Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
Jun 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Scholar Rock, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD
Conditions
- Facioscapulohumeral Muscular Dystrophy
- FSHD
Interventions
ApitegromabDrug
Apitegromab (SRK-015) is a fully human anti-promyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
PlaceboDrug
Placebo is administered every 4 weeks by intravenous (IV) infusion and does not contain the active ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the efficacy of apitegromab compared with placebo in participants with FSHDTime frame: 52 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Neuromuscular Research Institute
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.